Literature DB >> 6650540

Death from cerebral hypoperfusion during nitroprusside treatment of acute angiotensin-dependent hypertension.

D C Haas, D H Streeten, R C Kim, A N Naalbandian, A I Obeid.   

Abstract

A 37-year-old woman, while being treated with nitroprusside for acute hypertension due to an intramural renal artery hemorrhage, became blind on the fourth hospital day, comatose on the fifth, and brain dead on the seventh. Postmortem examination of her brain revealed border-zone infarcts in the parietal-occipital regions and cerebrellum of the sort associated with cerebral hypoperfusion due to hypotension. Yet her blood pressure had been lowered judiciously to a mean pressure in the vicinity of 110 to 120 mm Hg, and episodes of hypotension had been avoided. As possible explanations for this unusual complication, the roles of acute hyperangiotensinemia and nitroprusside administration are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6650540     DOI: 10.1016/0002-9343(83)90891-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

Review 1.  Secondary hypertension. An overview of its causes and management.

Authors:  D H Streeten; G H Anderson
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

2.  CT perfusion imaging in the management of posterior reversible encephalopathy.

Authors:  S O Casey; A McKinney; M Teksam; H Liu; C L Truwit
Journal:  Neuroradiology       Date:  2004-03-26       Impact factor: 2.804

Review 3.  Funduscopy in hypertensive emergencies: Detecting flames in the cotton fields.

Authors:  Fouad Amraoui; Bert-Jan H van den Born
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-10-03       Impact factor: 3.738

4.  Funduscopy: Yes or no? Hypertensive emergencies and retinopathy in the emergency care setting; a retrospective cohort study.

Authors:  Charlotte M Nijskens; Saskia R Veldkamp; Dymph J Van Der Werf; Arnold H Boonstra; Marije Ten Wolde
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-10-05       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.